FDA approves Roche's tPSA and fPSA tests:
This article was originally published in Clinica
Roche Diagnostics has gained US FDA approval for two prostate specific antigen (PSA) tests for prostate cancer. The Elecsys total PSA (tPSA) and Elecsys free PSA are automated blood tests that are run on the company's Elecsys immunoassay systems. The tPSA is a prostate cancer screening test for use in conjunction with a digital rectal examination (DRE). The fPSA is to be used with the tPSA test to calculate the ratio of fPSA to tPSA, a figure useful in distinguishing prostate cancer from benign conditions in men with an elevated PSA but a normal DRE.
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.